CB-ChMF-11 is the product that we are developing for the treatment of Preeclampsia representing an important improvement for the health of millions of mothers and children, and a substantial saving for health systems in developed Countries.

Preeclampsia affects 3-8% of all pregnancies worldwide, thus being the main cause of fetal-maternal mortality and morbidity worldwide. Preeclampsia is associated with Fetal Growth Restriction. Importantly, even though Preeclampsia resolves at delivery with placenta removal, it may cause severe long-term complications for both the mother and the newborn as cardiovascular and metabolic diseases, diabetes, neonatal neurological impairment, cerebral palsy and an increased risk of intellectual disability and autism spectrum disorders. It is evident that Preeclampsia has a massive social-economic burden, costing to the global health care system more than 3 billion USD/year with lifetime medical intervention.

There are no effective therapeutic interventions for Preeclampsia except for a timed and often premature delivery, that represents itself an important risk factor for the newborn’s health.
Our technology is based on hPDMSCs isolated from healthy human term placenta immediately after delivery, purified, expanded and cultured in-vitro in order to naturally obtain CB-ChMF-11 that is currently in nonclinical development stage.

A Proof of Concept study to verify the efficacy of CB-ChMF-11 on a recognized Preeclampsia animal model has been successfully completed. It demonstrated that the product reverts maternal hypertension and proteinuria, significantly improves fetal outcomes, and inhibits the expression of placental biomarkers associated with the syndrome.

CB-ChMF-11 therapeutic approach for Preeclampsia is patented in EU, USA, and Canada.